Siegfried Group: Change in the Executive Committee
Rudolf Hanko (born 1955) assumed operational responsibility for Siegfried as CEO in 2009. Andreas Casutt, Chairman of Siegfried: «Rudolf Hanko has had a significant effect on our company in the past nine years, and he played a decisive role in Siegfried’s continuing success. His term of office is characterized by the development of annual sales from 260 to over 700 million Swiss francs and, especially, by the targeted expansion of our production sites and the consistent orientation of our company toward meeting the fast changing needs of pharmaceutical companies with international operations. The Board of Directors expresses its thanks to Rudolf Hanko for his great achievements on behalf of the company and is glad he will remain closely connected with Siegfried».
Wolfgang Wienand (born 1972) joined Siegfried’s Executive Committee in 2010, and as Chief Scientific & Strategy Officer he is responsible for global research and development activities and for Strategy, Mergers & Acquisitions, Legal, IP Management and Regulatory Affairs. Andreas Casutt: «The Board of Directors is pleased to appoint the new CEO from within the company. Wolfgang Wienand has made a decisive contribution toward implementation of our corporate strategy by means of successful acquisitions in recent years. He demonstrated significant leadership qualities as the person responsible for overseeing the post-merger integration of the new corporate entities and as global head of Research and Development. Thus Wolfgang Wienand has all the prerequisites to lead our company as CEO into a successful future».
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.